ReviewClinical and molecular hepatology2023
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future.
Review in Clinical and molecular hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Near-Infrared Fluorescent Lipid Droplet Polarity Probe for Distinguishing Different Liver Injury Diseases.Chemical & biomedical imaging · 2026Article
- Performance of three clinical scores for steatosis and steatohepatitis and their interaction with metabolic syndrome in obese individuals.World journal of hepatology · 2026Article
- Diagnostic performance of controlled attenuation parameter for grading hepatic steatosis in MASLD: an MRI-PDFF-referenced study in a Chinese cohort.Frontiers in medicine · 2026Article
- 3D multiparametric ultrasound imaging of steatotic liver disease in a study with male rats.Nature communications · 2025Article
- Discovery of ultrasound-derived fat fraction as a non-invasive tool for MASLD diagnosis.European journal of medical research · 2025Article
- Quantification of liver steatosis of metabolic dysfunction-associated steatotic liver disease based on body composition analysis.Scientific reports · 2025Article
- The application performance of MRI-PDFF detection values of different hepatic lobes in diagnosing liver steatosis.Clinical and experimental medicine · 2025Article
- Thyroid Stimulating Hormone Levels Are Related to Fatty Liver Indices Independently of Free Thyroxine: A Cross-Sectional Study.Journal of clinical medicine · 2025Article
- From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome - current insights and future directions.Clinical diabetes and endocrinology · 2024Review
- Correspondence to editorial on "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis".Clinical and molecular hepatology · 2024Article
- Utilizing fully-automated 3D organ segmentation for hepatic steatosis assessment with CT attenuation-based parameters.European radiology · 2024Article
- Head-to-head comparison of three different US-based quantitative parameters for hepatic steatosis assessment: a prospective study.Abdominal radiology (New York) · 2024Article
- Non-small cell lung cancer and immune checkpoint inhibitor therapy: does non-alcoholic fatty liver disease have an effect?BMC cancer · 2024Article
- Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis.The Kaohsiung journal of medical sciences · 2024Article
- Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis.Journal of clinical medicine · 2023Article
- Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future.Clinical and molecular hepatology · 2023Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease is currently the most common chronic liver disease, affecting up to 25% of the global population. Simple fatty liver, in which fat is deposited in the liver without fibrosis, has been regarded as a benign disease in the past, but it is now known to be prognostic. In the future, more emphasis should be placed on the quantification of liver fat. Traditionally, fatty liver has been assessed by histological evaluation, which requires an invasive examination; however, technological innovations have made it possible to evaluate fatty liver by non-invasive imaging methods, such as ultrasonography, computed tomography, and magnetic resonance imaging. In addition, quantitative as well as qualitative measurements for the detection of fatty liver have become available. In this review, we summarize the currently used qualitative evaluations of fatty liver and discuss quantitative evaluations that are expected to further develop in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.